NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of stem cell products, today announced that it has submitted a Pre-Investigational New Drug (Pre-IND) document to the Food and Drug Administration (FDA) for PLX-I, the Company’s first product. An innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells, PLX- I is expected to be used to improve the engraftment of Umbilical Cord Blood when treating blood cancer and blood disorders. Approval of the Pre-IND document by the FDA precedes initiation of Phase I trials.
